Press release
Deadline on October 18th coming up in Lawsuit for Investors in Sesen Bio, Inc. (NASDAQ: SESN)
A Deadline is coming up on October 18, 2021 in the lawsuit for certain investors in Sesen Bio, Inc. (NASDAQ: SESN).
Investors who purchased shares of Sesen Bio, Inc. (NASDAQ: SESN) have certain options and there are strict and short deadlines running. Deadline: October 18, 2021. NASDAQ: SESN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Sesen Bio, Inc. (NASDAQ: SESN)common shares between December 21, 2020 and August 17, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between December 21, 2020 and August 17, 2021, the Defendants failed to disclose to investors, that Sesen Bio’s clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as “major”, that three of Sesen Bio’s clinical investigators were found guilty of “serious noncompliance,” including “back-dating data”, that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum, that Sesen Bio’s clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury, that, as a result of the foregoing, the Company’s BLA for Vicineum was not likely to be approved, that, as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Sesen Bio, Inc. (NASDAQ: SESN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on October 18th coming up in Lawsuit for Investors in Sesen Bio, Inc. (NASDAQ: SESN) here
News-ID: 2403180 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Sesen
Non-Muscle Invasive Bladder Cancer (NMIBC) market is anticipated to witness sign …
In 2023, the Non Muscle Invasive Bladder Cancer Therapeutics Market Size in the 7MM was approximately USD 2,350 million. This is expected to grow in the coming years due to the increasing Non Muscle Invasive Bladder Cancer Prevalence in the market, the launch of high-priced therapies, and the rising number of active companies in this field.
DelveInsight has released a new report titled "Non-Muscle Invasive Bladder Cancer - Market Insights, Epidemiology,…
Sesen Launches with a Singular Mission: Advancing Life Sciences Globally Through …
Boston, MA - Today marks the official launch of Sesen, a next-generation language services company purpose-built to meet the complex demands of the life sciences industry. Specializing exclusively in translation, localization, and AI-enhanced linguistic solutions for pharmaceutical, biotechnology, medical device, CRO, and regulatory organizations, Sesen combines industry expertise with cutting-edge technology to deliver faster, more accurate, and fully compliant multilingual communications across 150+ languages.
Built by industry veterans, Sesen is…
Non-Muscle Invasive Bladder Cancer Market Industry Analysis by Size, Share, Grow …
Introduction
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is poised for significant growth as advancements in intravesical therapies, immuno-oncology drugs, and molecular diagnostics improve patient outcomes. NMIBC, which accounts for about 70-75% of all newly diagnosed bladder cancer cases, is characterized by high recurrence rates but relatively low mortality compared to muscle-invasive forms. The rising global prevalence, particularly among aging populations, is prompting greater investment in early diagnosis, novel drug delivery…
Non-Muscle Invasive Bladder Cancer Market: Epidemiology, Therapies, Companies, D …
Non-Muscle Invasive Bladder Cancer therapies are expected to boost the Non-Muscle Invasive Bladder Cancer Market in the upcoming years.
DelveInsight has launched a new report on "Non-Muscle Invasive Bladder Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Non-Muscle Invasive Bladder Cancer, historical and forecasted epidemiology as well as the Non-Muscle Invasive Bladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Non-Muscle Invasive Bladder Cancer Pipeline Analysis (2023) Covering Clinical Tr …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the Non-Muscle Invasive Bladder Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Non-Muscle Invasive Bladder Cancer…
Investigation announced for Long-Term Investors in NASDAQ: SESN shares over poss …
An investigation was announced concerning possible breaches of fiduciary duties by certain directors of Sesen Bio, Inc..
Investors who are current long term investors in Sesen Bio, Inc. (NASDAQ: SESN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SESN stocks follows a lawsuit filed against Sesen Bio,…
